Fortress Biotech (NASDAQ:FBIO) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.
Institutional & Insider Ownership
32.1% of Fortress Biotech shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 29.5% of Fortress Biotech shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and price targets for Fortress Biotech and Regeneron Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Fortress Biotech | 0 | 0 | 6 | 0 | 3.00 |
Regeneron Pharmaceuticals | 0 | 5 | 14 | 1 | 2.80 |
Fortress Biotech presently has a consensus target price of $10.75, suggesting a potential upside of 160.92%. Regeneron Pharmaceuticals has a consensus target price of $646.2609, suggesting a potential upside of 28.58%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Regeneron Pharmaceuticals.
Valuation and Earnings
This table compares Fortress Biotech and Regeneron Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Fortress Biotech | $36.63 million | 10.67 | $-39,960,000.00 | ($0.73) | -5.64 |
Regeneron Pharmaceuticals | $7.86 billion | 6.85 | $2.12 billion | $21.47 | 23.41 |
Regeneron Pharmaceuticals has higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Fortress Biotech has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.
Profitability
This table compares Fortress Biotech and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Fortress Biotech | -131.98% | -44.08% | -19.06% |
Regeneron Pharmaceuticals | 38.28% | 28.97% | 20.11% |
Summary
Regeneron Pharmaceuticals beats Fortress Biotech on 10 of the 15 factors compared between the two stocks.